ORPHA:521305
Proximal myopathy with focal depletion of mitochondria
Query health: suspect — Only one of 2 strategies returned hits (phrase).
Publications
3
8th percentile
Trials
0
Interventional, condition-specific
Researchers
20
Distinct authors in sample
Gene link
—
Readiness
3/6
Stages with a signal
Clinical definition (Orphanet)
A rare genetic neuromuscular disease characterized by late onset of mild, , proximal muscle weakness, severe myalgias during and after exercise, and susceptibility to rhabdomyolysis. is mild or absent. There are no abnormalities of the skin. Muscle biopsy shows focal depletion of mitochondria especially at the center of muscle fibers, surrounded by enlarged mitochondria at the periphery.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0010923
- MeSH:C563453
- OMIM:600706
- UMLS:C1833453
Additional Mondo synonyms (1)
proximal myopathy with focal depletion of mitochondria
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
3/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3 matched papers (1 in last 10 years) Source
- Phenotype characterisedPresent
3 HPO annotations (e.g. Elevated circulating creatine kinase activity; Exercise-induced myalgia; Proximal muscle weakness) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 182 for broader category myopathy
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
3
Associated phenotypes · MONDO:0010923
- Elevated circulating creatine kinase activity
- Exercise-induced myalgia
- Proximal muscle weakness
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3
3 papers have ever been indexed under this name. For scale, breast cancer has over 700,000. Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1 in the last 10 years · high confidence · 8th percentile (publications denominator)
Phrase hits: 3 · MeSH hits: 0
Who's working on it?
20
Distinct author names in 3 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Aldana-Hernandez P1 paper · 2019
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.
Papers in Europe PMC - 02Beckmann ND1 paper · 2019
Graduate School of Biological Sciences, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1020, New York, NY, 10029, USA.
Papers in Europe PMC - 03Brady L1 paper · 2016
Department of Pediatrics, McMaster University Medical Centre, 1200 Main Street West, Hamilton, Ontario L8N 3Z5, Canada.
Papers in Europe PMC - 04Chipuk JE1 paper · 2019
Department of Oncological Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, 10029, USA.
Papers in Europe PMC - 05Curtis J1 paper · 2019
Department of Agricultural, Food and Nutritional Science, University of Alberta, Edmonton, Alberta, T6G 2E1, Canada.
Papers in Europe PMC - 06Devarakonda PM1 paper · 2019
Department of Molecular & Cell Biology, University of Connecticut, Storrs, CT, 06269, USA.
Papers in Europe PMC - 07Giri M1 paper · 2016
Children's National Medical Center, Research Center for Genetic Medicine, 111 Michigan Ave, Washington D.C. 20010, USA.
Papers in Europe PMC - 08Goel AJ1 paper · 2019
Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1020, New York, NY, 10029, USA.
Papers in Europe PMC - 09Goldhamer DJ1 paper · 2019
Department of Molecular & Cell Biology, University of Connecticut, Storrs, CT, 06269, USA.
Papers in Europe PMC - 10Guo YP1 paper · 1992
Department of Neurology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 182 trials are registered for myopathy, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
high confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
182 interventional trials matched myopathy, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: myopathy
182
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07412821·ENROLLING BY INVITATION·A Phase 1b Study of Adenylosuccinic Acid (ASA-001) for Adenylosuccinate Synthase 1 (ADSS1) Deficient Myopathy.
Conditions: Adenylosuccinate Synthase 1 Deficient Myopathy·Matched via name phrase
- NCT06371417·RECRUITING·Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Conditions: Antiphospholipid Syndrome (APS) · Bullous Pemphigoid (BP) · Behçet's Syndrome (BS) · Dermatomyositis (DM)·Matched via name phrase
- NCT06794008·RECRUITING·BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus · Inflammatory Myopathy · Systemic Sclerosis (SSc) · ANCA-associated Vasculitis·Matched via name phrase
- NCT07293988·RECRUITING·Spastic Myopathy in Adults With Cerebral Palsy
Conditions: Cerebral Palsy (CP)·Matched via name phrase
- NCT05312424·RECRUITING·Annatto-derived GG for Statin-associated Myopathy
Conditions: Myopathy; Primary·Matched via name phrase
- NCT07490275·NOT YET RECRUITING·Allogeneic CD19/BCMA-Targeted CAR-γδT Cell Therapy: Safety and Preliminary Pharmacodynamics in Relapsed/Refractory Autoimmune Diseases
Conditions: Refractory/Relapsed Systemic Lupus Erythematosus · Refractory / Relapsed / Progressive Systemic Sclerosis · Refractory / Relapsing / Progressive Inflammatory Myopathy · Refractory / Relapsed Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis·Matched via name phrase
- NCT05979441·ENROLLING BY INVITATION·A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
Conditions: Myositis · Active Idiopathic Inflammatory Myopathy · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT04086329·RECRUITING·Validation of Oxygen Nanosensor in Mitochondrial Myopathy
Conditions: Mitochondrial Myopathies · Mitochondrial Diseases·Matched via name phrase
- NCT04678635·RECRUITING·Chronic Transcranial Direct Current Stimulation in Patients With Systemic Autoimmune Myopathies
Conditions: Myopathy·Matched via name phrase
- NCT07339540·RECRUITING·the Safety and Efficacy of Targeted BCMA In Vivo LV Injection for Recurrent or Refractory Autoimmune Diseases
Conditions: Recurrent or Refractory Systemic Lupus Erythematosus · Recurrent or Refractory IgG4 Related Diseases · Recurrent or Refractory Systemic Sclerosis · Recurrent or Refractory Idiopathic Inflammatory Myopathy·Matched via name phrase
- NCT07676266·NOT YET RECRUITING·A Study of C-CAR168 in the Treatment of Autoimmune Diseases Refractory to Standard Therapy
Conditions: Multiple Sclerosis (MS) · Myasthenia Gravis (MG) · Neuromyelitis Optica Spectrum Disorder · Systemic Lupus Erythematosus·Matched via name phrase
- NCT06614270·RECRUITING·Anti-CD19 IL-10/IL15 CAR-NK Cells in Refractory/Relapsed Autoimmune Diseases
Conditions: Systemic Sclerosis (SSc) · ANCA Associated Vasculitis (AAV) · Idiopathic Inflammatory Myopathy (IIM) · Sjogren's Syndrome·Matched via name phrase
- NCT07085676·RECRUITING·Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases
Conditions: Systemic Sclerosis (SSc) · Idiopathic Inflammatory Myopathy (IIM) · Rheumatoid Arthritis (RA) · Systemic Lupus Erythematosus (SLE)·Matched via name phrase
- NCT05859997·ENROLLING BY INVITATION·Universal CAR-T Cells (BRL-301) in Relapse or Refractory Autoimmune Diseases
Conditions: Systemic Lupus Erythematosus (SLE) · Sjogren's Syndrome · Systemic Sclerosis · Inflammatory Myopathy·Matched via name phrase
- NCT07450690·RECRUITING·Exercise Training Effects on Muscle Function in Adults With Mitochondrial Myopathy
Conditions: Mitochondrial Diseases · Mitochondrial Myopathy·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Proximal myopathy with focal depletion of mitochondria — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Proximal myopathy with focal depletion of mitochondria" OR "Proximal myopathy with focal depletion of the mitochondria"
MeSH descriptor terms unioned into the query: Proximal Myopathy with Focal Depletion of Mitochondria
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Proximal myopathy with focal depletion of mitochondria" OR "Proximal myopathy with focal depletion of the mitochondria"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"myopathy"
Query health: suspect — strategies attempted: phrase, mesh; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T18:02:23.356Z
